🇺🇸 FDA
Pipeline program

MR-130A-01

MR-130A-01-TD-2002

Phase 2 small_molecule active

Quick answer

MR-130A-01 for Investigation of maintenance of ovulation inhibition after intentional application errors for indication of contraception in healthy subjects is a Phase 2 program (small_molecule) at Mylan dura GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Mylan dura GmbH
Indication
Investigation of maintenance of ovulation inhibition after intentional application errors for indication of contraception in healthy subjects
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials